NeuColl Inc.

Ever since drug-eluting stents became such an overwhelming success, the health care products industry has been trying to wrap its arms around convergence opportunities, in which the combination of dru

As Angiotech creates follow-ons to its drug-eluting stent, it's pursuing a niche strategy that requires a complex set of resources across opposite industries, and blends the divergent risks and reward